Please check your internet connection and try again.
# Hyoscine Butylbromide
## Overview
Hyoscine butylbromide (scopolamine butylbromide) is a quaternary ammonium antispasmodic agent. Unlike hyoscine hydrobromide, it does not cross the blood-brain barrier significantly, resulting in fewer central anticholinergic effects. It acts as a competitive antagonist at muscarinic receptors in the gastrointestinal, biliary, and urinary tracts.
## Primary Indications
* Symptomatic relief of gastrointestinal, biliary, and genitourinary smooth muscle spasms.
* Adjunct in diagnostic procedures (e.g., radiology of the GI tract).
* Palliative care (management of "death rattle" or respiratory secretions - off-label).
## Adult Dosing
* **Oral:** 10–20 mg three to four times daily. Maximum daily dose: 80–100 mg.
* **IV/IM/SC:** 20 mg as a single dose. May be repeated after 30 minutes if necessary. Maximum daily dose: 100 mg.
## Pediatric Dosing
* **Children 6–12 years:** 10 mg (one tablet) three times daily.
* **IV/IM/SC:** 0.3–0.6 mg/kg/dose.
* *Note:* Use with caution. Pediatric dosing varies by local institutional protocol; confirm with local formulary or pediatric specialist.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal standardized adjustment, but use with caution; monitor for increased anticholinergic toxicity.
* **Elderly:** Use cautiously; higher risk of urinary retention, constipation, and tachycardia.
## Contraindications
* Hypersensitivity to hyoscine butylbromide.
* Myasthenia gravis.
* Mechanical intestinal obstruction or paralytic ileus.
* Megacolon.
* Narrow-angle glaucoma.
* Tachycardia or unstable cardiovascular conditions.
* Prostatic hypertrophy (with urinary retention).
## Adverse Effects
* **Common:** Dry mouth, xerophthalmia (dry eyes), blurred vision, tachycardia, constipation, and urinary retention.
* **Serious:** Anaphylaxis, cardiac arrhythmias (especially with IV administration), and acute angle-closure glaucoma.
## Key Drug Interactions
* **Anticholinergics:** Enhanced effects and toxicity (e.g., antidepressants, antihistamines, antipsychotics).
* **Metoclopramide:** Antagonistic effect on gastrointestinal prokinetic activity.
* **Potassium Chloride:** Increased risk of gastrointestinal ulceration if administered concurrently with solid oral dosage forms.
## Monitoring
* Monitor heart rate and rhythm, particularly after parenteral administration.
* Assess for urinary output, especially in elderly patients or those with existing prostatism.
* Assess for signs of elevated intraocular pressure if visual disturbances occur.
## Clinical Pearls
* **IV Administration:** Administer slowly. Rapid IV injection may cause tachycardia and hypotension.
* **Systemic Absorption:** Oral bioavailability is low; use IV or SC routes if a rapid effect is required.
* **Pregnancy/Lactation:** Use only if the therapeutic benefit outweighs the potential risk. Generally avoided unless essential.
* **Not for GERD:** Avoid in patients with gastroesophageal reflux disease as it may exacerbate symptoms by decreasing lower esophageal sphincter tone.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing and clinical guidelines may vary by region, institutional protocol, or specific patient factors. Always verify current prescribing information, package inserts, and local clinical guidelines before administration.
